公开(公告)号：EP3824905A1

公开(公告)日：2021-05-26

申请号：EP20201497.3

申请日：2013-08-20

申请人： Fred Hutchinson Cancer Research Center ,  Seattle Children's Hospital, dba Seattle Children's Research Institute

发明人： Riddell, Stanley R. ,  Hudecek, Michael ,  Jensen, Michael

IPC分类号： A61K39/395 ,  C07K14/705 ,  C12N5/10 ,  C12N15/62

摘要： The present invention provides nucleic acids, vectors, host cells, methods and compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring CD8+ central memory T cells or combinations of central memory T cells with CD4+ T cells that are genetically modified to express a chimeric receptor. In embodiments the genetically modified host cell comprises a nucleic acid comprising a polynucleotide coding for a ligand binding domain, a polynucleotide comprising a customized spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain. It has been surprisingly found that the length of the spacer region can affects the ability of chimeric receptor modified T cells to recognize target cells in vitro and affects in vivo efficacy of the chimeric receptor modified T cells. Pharmaceutical formulations produced by the method, and methods of using the same, are also described.

公开(公告)号：EP4006056A1

公开(公告)日：2022-06-01

申请号：EP21204990.2

申请日：2017-02-02

申请人： Fred Hutchinson Cancer Research Center

发明人： Balakrishnan, Ashwini ,  Hoffstrom, Benjamin G. ,  Randolph-Habecker,, Julie ,  Riddell, Stanley R.

IPC分类号： C07K16/28 ,  A61K39/00 ,  A61P1/18 ,  A61P11/00 ,  A61P15/00 ,  A61P35/00 ,  A61P35/02 ,  C07K14/725 ,  A61P35/04

摘要： The present disclosure relates to anti-RORl binding proteins, including those that bind to a ROR1 or portion thereof such as an intracellular C terminal portion of a ROR1 protein, and the use of such binding proteins in immunohistochemical and diagnostic methods. Related kits and methods of using the binding proteins are also provided, as are methods of treatment of subjects having diseases or conditions determined to be candidates for such treatments by the binding proteins or methods of this disclosure.